Today: 11 June 2026
WiseTech Global stock slides 4.7%: AI job cuts, CEO buy and dividend dates now in focus

WiseTech Global stock slides 4.7%: AI job cuts, CEO buy and dividend dates now in focus

SYDNEY, March 2, 2026, 18:28 AEDT — Market closed

Shares of WiseTech Global Ltd fell 4.7% on Monday to A$45.29, after swinging between A$43.90 and A$46.09 in the session.

The pullback lands as investors try to work out what WiseTech’s AI push means in practice — fewer people, faster code, and whether service levels hold up while the company is still digesting a big acquisition.

WiseTech last week flagged about 2,000 job cuts as part of an AI-led overhaul, with CEO Zubin Appoo arguing “the era of manually writing code as the core act of engineering is over.” Shares jumped 11.1% that day, but the stock remained 68% below its November 2024 peak; Marc Jocum, senior product and investment strategist at Global X ETFs, said the recent weakness was “more governance-driven than fundamental.” Reuters

Broader markets were steady, but tech lagged. The S&P/ASX 200 closed up 0.03% while the All Tech index fell 2.52% and the information technology sector slid 3.07% as weekend escalation around Iran pushed investors toward energy and other defensives.

In its half-year results release, WiseTech reported total revenue of $672.0 million in the six months to Dec. 31, with underlying net profit after tax of $114.5 million and statutory net profit of $68.1 million. It reaffirmed FY26 guidance for revenue of $1.39 billion–$1.44 billion and EBITDA — earnings before interest, tax, depreciation and amortisation, a common cash-earnings yardstick — of $550 million–$585 million.

A separate filing late last week showed Appoo bought 20,020 WiseTech shares for a total A$1,000,049.19, purchased on-market on Feb. 26 and expected to settle on March 2.

The workforce plan has also drawn scrutiny from labour groups. Professionals Australia, a union representing tech and engineering workers, sought an urgent meeting with WiseTech and said “the introduction of AI on this scale is clearly a major workplace change.” Reuters

For now, the debate in the market is less about this week’s numbers and more about execution. Investors want signs the company can take costs out without choking product delivery or customer support, and without dragging the e2open integration back into the headlines.

But it can still go wrong. Restructuring can cost money upfront, timelines can slip, and staff pushback can slow changes — and any hit to global trade volumes would test a business built on transactions moving through logistics and supply-chain systems.

Next up is the interim dividend timetable. WiseTech’s shares go ex-dividend on March 13 — meaning buyers from that date do not get the upcoming payout — with a March 16 record date and an April 10 payment date, according to an ASX notice.

Stock Market Today

  • How to Invest Indirectly in SpaceX Before IPO Through ETFs
    June 11, 2026, 10:46 AM EDT. Investors can gain indirect exposure to SpaceX ahead of its IPO via ETFs like ERShares Private-Public Crossover ETF (XOVR) and AGIX. These funds use special purpose vehicles (SPVs)-legal entities holding SpaceX shares-to navigate SEC rules allowing up to 15% allocation in illiquid private companies. XOVR holds about 13.2% exposure to SpaceX through SPVs, while AGIX combines SPV investments with a small direct stake. Investors should note these ETFs are thematic portfolios with broad tech focuses and relatively high expense ratios. Direct public investment remains available only after SpaceX's Nasdaq debut at ticker SPCX on June 12, priced around $135, targeting a $1.75-$2 trillion valuation.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Qantas share price slides on Iran conflict and oil spike — what investors watch next
Previous Story

Qantas share price slides on Iran conflict and oil spike — what investors watch next

Vodafone stock price dips after Amazon Leo satellite deal; VOD.L investors eye May results
Next Story

Vodafone stock price dips after Amazon Leo satellite deal; VOD.L investors eye May results

Go toTop